Breaking News
Bioved Pharmaceuticals announces the launch of its Proprietary Natural Products for Animal Health, with its Shwan Ayurved™ Science
Bioved Pharmaceuticals has announced the launch of its scientifically validated Natural Animal Health products from the science of Ayurveda. Bioved is a Discovery Platform for safe and effective plant-based nutraceuticals, dietary supplements and OTC products for human health, that have undergone extensive pre-clinical and clinical testing for difficult-to-treat disorders. It’s products are sold in several countries of the world over 3 continents. Bioved now brings that knowledge and experience to the animal kingdom, under the science of Shwan (Dog) Ayurved™.
“We are very excited with this new phase in our company. This is truly the humanization of pets. We take technology and products that have been clinically tested in human beings, and have all the underlying safety and efficacy studies. We have developed a line of products in natural and tasty chews for dogs initially. The line includes Anitrex® for bone and joint health, Anilean® for weight management, Ammunex™ for boosting immunity and Anilive™ for liver health. Each of these have a multitude of studies and peer-reviewed scientific publications for use in humans. The animal kingdom will now benefit from this going forward. We also have stability and palatibility studies with the animal chews. As with our human products, each batch is tested to be free from residual solvents, pesticides, bacterial contamination and heavy metals. We maintain the highest standards of manufacturing in the US, and will be extending the line to other companion and large animals” said Dr Deben Dey, Chief Scientific Officer of Bioved.
The herbs or plants used in each of the animal products are extracted by a Bioved US patented method, and standardized and validated by modern biotechnology processes. “We are launching these products at the Western Veterinary Conference February 19th – 22nd, 2023 in Las Vegas,” said Dr Deepa Chitre, the Chief Executive Officer of Bioved. “Our pets bring so much happiness to us, this is just a small token of giving back to them,” she added.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more